BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 2019;18:415-25. [PMID: 31066297 DOI: 10.1080/14740338.2019.1612872] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-Furst F, Pieringer H, Puchner R, Flick H, Salzer HJF, Weiss G, Winkler S, Skvara H, Moschen A, Hofer H, Feurstein J, Sautner J. National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). Wien Klin Wochenschr 2022. [PMID: 36036323 DOI: 10.1007/s00508-022-02062-7] [Reference Citation Analysis]
2 Ting SW, Ting SY, Lin YS, Lin MS, Kuo G. Association between different systemic therapies and the risk of tuberculosis in psoriasis patients: A population-based study. Int J Clin Pract 2021;:e15006. [PMID: 34773345 DOI: 10.1111/ijcp.15006] [Reference Citation Analysis]
3 Petruccioli E, Petrone L, Chiacchio T, Farroni C, Cuzzi G, Navarra A, Vanini V, Massafra U, Lo Pizzo M, Guggino G, Caccamo N, Cantini F, Palmieri F, Goletti D. Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease. Front Immunol 2021;12:716857. [PMID: 34447382 DOI: 10.3389/fimmu.2021.716857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 D'Abramo A, Vita S, Maffongelli G, Mariano A, Agrati C, Castilletti C, Goletti D, Ippolito G, Nicastri E; Spallanzani COVID-19 Case Investigation Team. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. Int J Infect Dis 2021;107:247-50. [PMID: 33901654 DOI: 10.1016/j.ijid.2021.04.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zafari P, Golpour M, Hafezi N, Bashash D, Esmaeili SA, Tavakolinia N, Rafiei A. Tuberculosis comorbidity with rheumatoid arthritis: Gene signatures, associated biomarkers, and screening. IUBMB Life 2021;73:26-39. [PMID: 33217772 DOI: 10.1002/iub.2413] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Hejazi ME, Ahmadzadeh A, Khabbazi A, Ebrahimi A, Farmani M, Hejazi Y. Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents. BMC Infect Dis 2020;20:464. [PMID: 32615992 DOI: 10.1186/s12879-020-05166-5] [Reference Citation Analysis]
8 Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 2020;12:1759720X20930116. [PMID: 32612710 DOI: 10.1177/1759720X20930116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
9 Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 2020;19:861-72. [PMID: 32552289 DOI: 10.1080/14740338.2020.1774550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Arbués A, Brees D, Chibout SD, Fox T, Kammüller M, Portevin D. TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis. PLoS Pathog 2020;16:e1008312. [PMID: 32069329 DOI: 10.1371/journal.ppat.1008312] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
11 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
12 Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 2020;19:69-82. [PMID: 31847608 DOI: 10.1080/14740338.2020.1703946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Favalli EG, Matucci-Cerinic M, Szekanecz Z. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmun Rev 2020;19:102421. [PMID: 31733368 DOI: 10.1016/j.autrev.2019.102421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Fragoulis GE, Constantinou CA, Sipsas NV, Hyrich KL, Nikiphorou E. Tuberculosis in inflammatory arthritis: are biological therapies the only culprits? The Lancet Rheumatology 2019;1:e138-40. [DOI: 10.1016/s2665-9913(19)30012-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]